Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.Journal of Clinical Immunology|November 7, 2003
Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndromeY Shoenfeld, I Krause, F Kvapil, et al.Cancer Discovery|September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) EfficacyKyung W Song, Kyle A Edgar, Emily J Hanan, et al.Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.Bioorganic & Medicinal Chemistry Letters|April 2, 2013
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoformSteven T Staben, Chudi Ndubaku, Nicole Blaquiere, et al.The Journal of Rheumatology|July 2, 2004
Features associated with epilepsy in the antiphospholipid syndromeYehuda Shoenfeld, Shaul Lev, Ilan Blatt, et al.Lupus|October 7, 2022
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")Zeynep B Erton, Rebecca K Leaf, Danieli de Andrade, et al.Arthritis Care & Research|July 7, 2025
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of DefinitionsMedha Barbhaiya, Stephane Zuily, Deanna Jannat-Khah, et al.Annals of the Rheumatic Diseases|September 20, 2008
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patientsR Cervera, M A Khamashta, Y Shoenfeld, et al.Pageof 12